Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front Immunol, 11, 572172
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther (in press)
T cell receptor therapy against melanoma-Immunotherapy for the future?
Scand J Immunol, 92 (4), e12927